留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Ⅰ型自身免疫性胰腺炎发病机制及研究进展

刘屹霄 杨莹韵 杨爱明

刘屹霄, 杨莹韵, 杨爱明. Ⅰ型自身免疫性胰腺炎发病机制及研究进展[J]. 协和医学杂志, 2023, 14(4): 826-832. doi: 10.12290/xhyxzz.2022-0517
引用本文: 刘屹霄, 杨莹韵, 杨爱明. Ⅰ型自身免疫性胰腺炎发病机制及研究进展[J]. 协和医学杂志, 2023, 14(4): 826-832. doi: 10.12290/xhyxzz.2022-0517
LIU Yixiao, YANG Yingyun, YANG Aiming. Advances in the Pathogenesis of Type Ⅰ Autoimmune Pancreatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 826-832. doi: 10.12290/xhyxzz.2022-0517
Citation: LIU Yixiao, YANG Yingyun, YANG Aiming. Advances in the Pathogenesis of Type Ⅰ Autoimmune Pancreatitis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(4): 826-832. doi: 10.12290/xhyxzz.2022-0517

Ⅰ型自身免疫性胰腺炎发病机制及研究进展

doi: 10.12290/xhyxzz.2022-0517
基金项目: 

国家自然科学基金 82073184

中央高水平医院临床科研业务费 2022-PUMCH-B-024

国家级大学生创新创业训练计划 202210023002

详细信息
    通讯作者:

    杨爱明, E-mail: yangaiming@medmail.com.cn

  • 中图分类号: R657.5+1; R593.2

Advances in the Pathogenesis of Type Ⅰ Autoimmune Pancreatitis

Funds: 

National Natural Science Foundation of China 82073184

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-024

National Innovation and Entrepreneurship Training Program for College Students 202210023002

More Information
  • 摘要: Ⅰ型自身免疫性胰腺炎(autoimmune pancreatitis,AIP)是一种以炎症和纤维化为主的胰腺炎,属于IgG4相关性疾病。目前关于Ⅰ型AIP的发病机制认识尚浅,普遍认为其发病是遗传、环境、免疫等多方面因素的综合结果。近年来,在Ⅰ型AIP发病的细胞和分子机制方面取得了诸多进展,本文主要从免疫学角度阐述其发病机制及研究进展。
    作者贡献:刘屹霄和杨莹韵负责查阅文献、撰写及修订论文;杨爱明负责设计选题和审校论文。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  Ⅰ型自身免疫性胰腺炎发病机制

    pDC:浆细胞样树突状细胞;IFN:干扰素;NET:中性粒细胞胞外杀菌网络;IL:白细胞介素;TGF:转化生长因子;BAFF:B淋巴细胞激活因子;PDGF:血小板衍生生长因子;CCL-18:趋化因子CC配体18;CTL: 细胞毒性T淋巴细胞

  • [1] Löhr JM, Vujasinovic M, Rosendahl J, et al. IgG4-related diseases of the digestive tract[J]. Nat Rev Gastroenterol Hepatol, 2022, 19: 185-97. doi:  10.1038/s41575-021-00529-y
    [2] Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology[J]. Pancreas, 2011, 40: 352-358. doi:  10.1097/MPA.0b013e3182142fd2
    [3] Naitoh I, Kamisawa T, Tanaka A, et al. Clinical characteristics of immunoglobulin IgG4-related sclerosing chol-angitis: Comparison of cases with and without autoimmune pancreatitis in a large cohort[J]. Dig Liver Dis, 2021, 53: 1308-1314. doi:  10.1016/j.dld.2021.02.009
    [4] Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan[J]. Pancreas, 2006, 32: 244-248. doi:  10.1097/01.mpa.0000202950.02988.07
    [5] Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy[J]. Pancreas, 2003, 27: 235-238.
    [6] Javed AA, Wright MJ, Ding D, et al. Autoimmune Pancreatitis: A Critical Analysis of the Surgical Experience in an Era of Modern Diagnostics[J]. Pancreas, 2021, 50: 556-563. doi:  10.1097/MPA.0000000000001812
    [7] Frulloni L, Scattolini C, Katsotourchi AM, et al. Exocrine and Endocrine Pancreatic Function in 21 Patients Suffering from Autoimmune Pancreatitis before and after Steroid Treatment[J]. Pancreatology, 2010, 10: 129-133. doi:  10.1159/000265945
    [8] Estrada P, Pfau P. Diagnosing autoimmune pancreatitis: choosing your weapon[J]. Gastrointest Endosc, 2020, 91: 382-384. doi:  10.1016/j.gie.2019.11.037
    [9] Arora K, Rivera M, Ting DT, et al. The histological diagnosis of IgG4-related disease on small biopsies: challenges and pitfalls[J]. Histopathology, 2019, 74: 688-698. doi:  10.1111/his.13787
    [10] Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese consensus guidelines for autoimmune pancreatitis, 2020[J]. J Gastroenterol, 2022, 57: 225-245. doi:  10.1007/s00535-022-01857-9
    [11] 张盼盼, 张文. IgG4相关性自身免疫性胰腺炎治疗中免疫抑制剂的应用[J]. 临床肝胆病杂志, 2018, 34: 1614-1618. doi:  10.3969/j.issn.1001-5256.2018.08.005
    [12] van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange[J]. Science, 2007, 317: 1554-1557. doi:  10.1126/science.1144603
    [13] Hubers LM, Vos H, Schuurman AR, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease[J]. Gut, 2018, 67: 728-735.
    [14] Shiokawa M, Kodama Y, Kuriyama K, et al. Pathogenicity of IgG in patients with IgG4-related disease[J]. Gut, 2016, 65: 1322-1332. doi:  10.1136/gutjnl-2015-310336
    [15] Wallace ZS, Mattoo H, Carruthers M, et al. Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations[J]. Ann Rheum Dis, 2015, 74: 190-195. doi:  10.1136/annrheumdis-2014-205233
    [16] Della-Torre E, Rigamonti E, Perugino C, et al. B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2020, 145: 968-981. doi:  10.1016/j.jaci.2019.07.004
    [17] Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, et al. Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis[J]. Hepatology (Baltimore, Md), 2013, 57: 2390-2398. doi:  10.1002/hep.26232
    [18] Sumimoto K, Uchida K, Kusuda T, et al. The role of CD19+CD24highCD38high and CD19+CD24highCD27+ regulatory B cells in patients with type 1 autoimmune pancreatitis[J]. Pancreatology, 2014, 14: 193-200. doi:  10.1016/j.pan.2014.02.004
    [19] Akitake R, Watanabe T, Zaima C, et al. Possible involvement of T helper type 2 responses to Toll-like receptor ligands in IgG4-related sclerosing disease[J]. Gut, 2010, 59: 542-545. doi:  10.1136/gut.2009.200972
    [20] Suzuki K, Tamaru J, Okuyama A, et al. IgG4-positive multi-organ lymphoproliferative syndrome manifesting as chronic symmetrical sclerosing dacryo-sialadenitis with subsequent secondary portal hypertension and remarkable IgG4-linked IL-4 elevation[J]. Rheumatology (Oxford), 2010, 49: 1789-1791. doi:  10.1093/rheumatology/keq113
    [21] Meiler F, Klunker S, Zimmermann M, et al. Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll-like receptors[J]. Allergy, 2008, 63: 1455-1463. doi:  10.1111/j.1398-9995.2008.01774.x
    [22] Maehara T, Mattoo H, Ohta M, et al. Lesional CD4+ IFN-γ+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis[J]. Ann Rheum Dis, 2017, 76: 377-385. doi:  10.1136/annrheumdis-2016-209139
    [23] Mattoo H, Mahajan VS, Maehara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2016, 138: 825-838. doi:  10.1016/j.jaci.2015.12.1330
    [24] Pillai S, Perugino C, Kaneko N. Immune mechanisms of fibrosis and inflammation in IgG4-related disease[J]. Curr Opin Rheumatol, 2020, 32: 146-151. doi:  10.1097/BOR.0000000000000686
    [25] Boonpiyathad T, Satitsuksanoa P, Akdis M, et al. IL-10 producing T and B cells in allergy[J]. Semin Immunol, 2019, 44: 101326. doi:  10.1016/j.smim.2019.101326
    [26] Kusuda T, Uchida K, Miyoshi H, et al. Involvement of inducible costimulator-and interleukin 10-positive regulatory T cells in the development of IgG4-related autoimmune pancreatitis[J]. Pancreas, 2011, 40: 1120-1130. doi:  10.1097/MPA.0b013e31821fc796
    [27] Akiyama M, Suzuki K, Kassai Y, et al. Resolution of elevated circulating regulatory T cells by corticosteroids in patients with IgG4-related dacryoadenitis and sialoadenitis[J]. Int J Rheum Dis, 2016, 19: 430-432. doi:  10.1111/1756-185X.12725
    [28] Miyoshi H, Uchida K, Taniguchi T, et al. Circulating naïve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis[J]. Pancreas, 2008, 36: 133-140. doi:  10.1097/MPA.0b013e3181577553
    [29] Mattoo H, Mahajan VS, Della-Torre E, et al. De novo oligoclonal expansions of circulating plasmablasts in active and relapsing IgG4-related disease[J]. J Allergy Clin Immunol, 2014, 134: 679-687. doi:  10.1016/j.jaci.2014.03.034
    [30] Maehara T, Mattoo H, Mahajan VS, et al. The expansion in lymphoid organs of IL-4(+) BATF(+) T follicular helper cells is linked to IgG4 class switching in vitro[J]. Life Sci Alliance, 2018, 1: e201800050. doi:  10.26508/lsa.201800050
    [31] Akiyama M, Yasuoka H, Yoshimoto K, et al. Interleukin-4 contributes to the shift of balance of IgG subclasses toward IgG4 in IgG4-related disease[J]. Cytokine, 2018, 110: 416-419. doi:  10.1016/j.cyto.2018.05.009
    [32] Zhang J, Lian M, Li B, et al. Interleukin-35 Promotes Th9 Cell Differentiation in IgG4-Related Disorders: Experimental Data and Review of the Literature[J]. Clin Rev Allergy Immunol, 2021, 60: 132-145. doi:  10.1007/s12016-020-08803-8
    [33] Xia C, Liu C, Liu Y, et al. Increased Circulating Th1 and Tfh1 Cell Numbers Are Associated with Disease Activity in Glucocorticoid-Treated Patients with IgG4-Related Disease[J]. J Immunol Res, 2020, 2020: 3757015.
    [34] Moriyama M, Nakamura S. Th1/Th2 Immune Balance and Other T Helper Subsets in IgG4-Related Disease[J]. Curr Top Microbiol Immunol, 2017, 401: 75-83.
    [35] Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood[J]. Science, 1999, 284: 1835-1837. doi:  10.1126/science.284.5421.1835
    [36] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34: 637-650. doi:  10.1016/j.immuni.2011.05.006
    [37] Blasius AL, Beutler B. Intracellular toll-like receptors[J]. Immunity, 2010, 32: 305-315. doi:  10.1016/j.immuni.2010.03.012
    [38] Honda K, Takaoka A, Taniguchi T. Type Ⅰ interferon[corrected] gene induction by the interferon regulatory factor family of transcription factors[J]. Immunity, 2006, 25: 349-360. doi:  10.1016/j.immuni.2006.08.009
    [39] Kawai T, Sato S, Ishii KJ, et al. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6[J]. Nat Immunol, 2004, 5: 1061-1068. doi:  10.1038/ni1118
    [40] Watanabe T, Asano N, Fichtner-Feigl S, et al. NOD1 contributes to mouse host defense against Helicobacter pylori via induction of type Ⅰ IFN and activation of the ISGF3 signaling pathway[J]. J Clin Invest, 2010, 120: 1645-1662. doi:  10.1172/JCI39481
    [41] Minaga K, Watanabe T, Hara A, et al. Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease[J]. Front Immunol, 2021, 12: 713779. doi:  10.3389/fimmu.2021.713779
    [42] Arai Y, Yamashita K, Kuriyama K, et al. Plasmacytoid Dendritic Cell Activation and IFN-α Production Are Prominent Features of Murine Autoimmune Pancreatitis and Human IgG4-Related Autoimmune Pancreatitis[J]. J Immunol, 2015, 195: 3033-3044. doi:  10.4049/jimmunol.1500971
    [43] Kamata K, Watanabe T, Minaga K, et al. Intestinal dysbiosis mediates experimental autoimmune pancreatitis via activation of plasmacytoid dendritic cells[J]. Int Immunol, 2019, 31: 795-809. doi:  10.1093/intimm/dxz050
    [44] Watanabe T, Minaga K, Kamata K, et al. Mechanistic Insights into Autoimmune Pancreatitis and IgG4-related Disease[J]. Trends Immunol, 2018, 39: 874-889. doi:  10.1016/j.it.2018.09.005
    [45] Watanabe T, Yamashita K, Arai Y, et al. Chronic Fibro-Inflammatory Responses in Autoimmune Pancreatitis Depend on IFN-α and IL-33 Produced by Plasmacytoid Dendritic Cells[J]. J Immunol, 2017, 198: 3886-3896. doi:  10.4049/jimmunol.1700060
    [46] Moriyama M, Nakamura S. Potential Pathways in the Pathogenesis of IgG4-Related Disease[M]. Tokyo: Springer Japan, 2016: 43-54.
    [47] Qureshi A, Ghobrial Y, De Castro J, et al. Autoimmune pancreatitis-What we know and what do we have to know?[J]. Autoimmun Rev, 2021, 20: 102912. doi:  10.1016/j.autrev.2021.102912
    [48] Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity[J]. Nat Immunol, 2011, 12: 631-638. doi:  10.1038/ni.2045
    [49] Baenziger S, Heikenwalder M, Johansen P, et al. Trigger-ing TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology[J]. Blood, 2009, 113: 377-388. doi:  10.1182/blood-2008-04-151712
    [50] Tsuboi H, Nakai Y, Iizuka M, et al. DNA microarray analysis of labial salivary glands in IgG4-related disease: comparison with Sj gren's syndrome[J]. Arthritis Rheumatol, 2014, 66: 2892-2899. doi:  10.1002/art.38748
    [51] Akiyama M, Yasuoka H, Yoshimoto K, et al. CC-chemokine ligand 18 is a useful biomarker associated with disease activity in IgG4-related disease[J]. Ann Rheum Dis, 2018, 77: 1386-1387. doi:  10.1136/annrheumdis-2017-212110
    [52] Schwartz C, Eberle JU, Voehringer D. Basophils in inflammation[J]. Eur J Pharmacol, 2016, 778: 90-95. doi:  10.1016/j.ejphar.2015.04.049
    [53] Watanabe T, Yamashita K, Fujikawa S, et al. Involvement of activation of toll-like receptors and nucleotide-binding oligomerization domain-like receptors in enhanced IgG4 responses in autoimmune pancreatitis[J]. Arthritis Rheum, 2012, 64: 914-924. doi:  10.1002/art.33386
    [54] Bieneman AP, Chichester KL, Chen YH, et al. Toll-like receptor 2 ligands activate human basophils for both IgE-dependent and IgE-independent secretion[J]. J Allergy Clin Immunol, 2005, 115: 295-301. doi:  10.1016/j.jaci.2004.10.018
    [55] Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4[J]. Immunity, 2013, 38: 570-580. doi:  10.1016/j.immuni.2012.11.014
    [56] Shiokawa M, Kodama Y, Sekiguchi K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis[J]. Sci Transl Med, 2018, 10: eaaq0997. doi:  10.1126/scitranslmed.aaq0997
    [57] Perugino CA, AlSalem SB, Mattoo H, et al. Identification of galectin-3 as an autoantigen in patients with IgG(4)-related disease[J]. J Allergy Clin Immunol, 2019, 143: 736-745. doi:  10.1016/j.jaci.2018.05.011
  • 加载中
图(1)
计量
  • 文章访问数:  256
  • HTML全文浏览量:  53
  • PDF下载量:  79
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-09-10
  • 录用日期:  2022-10-05
  • 网络出版日期:  2022-11-09
  • 刊出日期:  2023-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!